This company has been acquired
TCR2 Therapeutics Management
Management criteria checks 3/4
TCR2 Therapeutics' CEO is Garry Menzel, appointed in Jan 2016, they has a tenure of 7.42 years. Their total yearly compensation is $1.74M , comprised of 34.5% salary and 65.5% bonuses, including company stock and options. They directly owns 1.03% of the company’s shares, worth $598.41K. The average tenure of the management team and the board of directors is 2.5 years and 3.8 years respectively.
Key information
Garry Menzel
Chief executive officer
US$1.7m
Total compensation
| CEO salary percentage | 34.5% |
| CEO tenure | 7.4yrs |
| CEO ownership | 1.0% |
| Management average tenure | 2.5yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely
Mar 08
Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?
Nov 23TCR² Therapeutics: Betting On A Solid Reversal
Aug 18TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Aug 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully
Jun 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth
Jan 11TCR2 Therapeutics: Trading Below Cash
Jan 06TCR2 Therapeutics: Trading Near Cash Value
Oct 12Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Sep 02TCR2 Therapeutics - Promising Technology And Upside Potential
Jun 15Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
Jun 04Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
Feb 19
TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Dec 28TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210
Dec 14TCR2 Therapeutics reports Q3 results
Nov 12TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity
Nov 10CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$163m |
| Dec 31 2022 | US$2m | US$603k | -US$152m |
| Sep 30 2022 | n/a | n/a | -US$119m |
| Jun 30 2022 | n/a | n/a | -US$115m |
| Mar 31 2022 | n/a | n/a | -US$107m |
| Dec 31 2021 | US$2m | US$580k | -US$100m |
| Sep 30 2021 | n/a | n/a | -US$91m |
| Jun 30 2021 | n/a | n/a | -US$81m |
| Mar 31 2021 | n/a | n/a | -US$73m |
| Dec 31 2020 | US$6m | US$560k | -US$67m |
| Sep 30 2020 | n/a | n/a | -US$61m |
| Jun 30 2020 | n/a | n/a | -US$58m |
| Mar 31 2020 | n/a | n/a | -US$53m |
| Dec 31 2019 | US$8m | US$492k | -US$97m |
| Sep 30 2019 | n/a | n/a | -US$96m |
| Jun 30 2019 | n/a | n/a | -US$100m |
| Mar 31 2019 | n/a | n/a | -US$107m |
| Dec 31 2018 | US$3m | US$436k | -US$62m |
| Sep 30 2018 | n/a | n/a | -US$55m |
| Dec 31 2017 | US$792k | US$423k | -US$15m |
Compensation vs Market: Garry's total compensation ($USD1.74M) is above average for companies of similar size in the US market ($USD752.41K).
Compensation vs Earnings: Garry's compensation has been consistent with company performance over the past year.
CEO
Garry Menzel (59 yo)
7.4yrs
Tenure
US$1,744,815
Compensation
Dr. Garry E. Menzel, Ph D., M.B.A. serves as an Independent Director at Black Diamond Therapeutics, Inc. since March 2017. He is a co-founder of Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.4yrs | US$1.74m | 1.03% $ 598.4k | |
| Chief Medical Officer | 6.4yrs | US$1.01m | 0.28% $ 162.0k | |
| Chief Business & Strategy Officer | 1.4yrs | US$1.07m | 0% $ 0 | |
| Founder & Member of the Advisory Board | no data | US$47.02k | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Operating Officer | less than a year | US$2.74m | 0.061% $ 35.7k | |
| Senior Director of Investor Relations & Corporate Communications | no data | no data | no data | |
| General Counsel | 5.4yrs | no data | no data | |
| Chief People Officer | 3.7yrs | no data | 0.12% $ 72.1k | |
| Vice President of Corporate Controller | 1.1yrs | no data | no data |
2.5yrs
Average Tenure
49yo
Average Age
Experienced Management: TCRR's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 7.4yrs | US$1.74m | 1.03% $ 598.4k | |
| Founder & Member of the Advisory Board | 1.7yrs | US$47.02k | no data | |
| Independent Director | 8.1yrs | no data | no data | |
| Independent Director | 5.3yrs | US$68.42k | 0% $ 0 | |
| Chairman of Advisory Board | no data | US$18.75k | 0% $ 0 | |
| Independent Chairman of the Board | 3.1yrs | US$95.92k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$63.42k | 0% $ 0 | |
| Independent Director | 3.2yrs | US$54.92k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$59.92k | 0% $ 0 | |
| Member of Advisory Board | no data | no data | no data | |
| Member of the Advisory Board | no data | no data | no data | |
| Member of Advisory Board | no data | no data | no data |
3.8yrs
Average Tenure
64yo
Average Age
Experienced Board: TCRR's board of directors are considered experienced (3.8 years average tenure).